Home > News > pSivida's biosilicon does its job, then goes away
May 27th, 2005
pSivida's biosilicon does its job, then goes away
Abstract:
Howard Lovy: Every one of pSivida's first "customers," are going to die. And they're going to die of the disease that the Australian nanobio company's product is designed to treat. But if BrachySil, the company's lead product, gives liver cancer patients the gift of another year of life without the pain of chemotherapy, then that would count as pSivida's first success.
Source:
Howard Lovy's NanoBot
Bookmark:
Nanomedicine
UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery May 22nd, 2013
Single-Cell Transfection Tool Enables Added Control for Biological Studies: McCormick researchers develop method of delivering molecules into targeted cells May 22nd, 2013
How Gold Nanoparticles Can Help Fight Ovarian Cancer May 21st, 2013
MU Researchers Develop Radioactive Nanoparticles that Target Cancer Cells: This is an early step toward developing therapies for metastasized cancers, MU scientist says May 21st, 2013